



The 1st & only medication in Canada indicated for the treatment of moderate to severe Binge Eating Disorder in adults¹

Dear Healthcare Professional,

Shire Pharma Canada ULC is pleased to announce that VYVANSE is now indicated for the treatment of moderate to severe Binge Eating Disorder in adults.²

The American Psychiatric Association now recognizes Binge Eating Disorder as a distinct disorder in the DSM-5[†] – a diagnostic change intended to increase the awareness of the substantial differences between BED and the common phenomenon of overeating.³ It also marks an opportunity to identify a newly recognized segment of patients.

VYVANSE should be prescribed for the shortest duration that is clinically indicated in order to minimize exposure to cardiovascular risk in this population; the risk-benefit profile of the drug for the individual patient should be periodically re-evaluated.

Consider VYVANSE for your adult patients with moderate to severe Binge Eating Disorder.

VYVANSE (lisdexamfetamine dimesylate capsules) is indicated for the treatment of Moderate to Severe Binge Eating Disorder (BED) in adults.

Recurrent episodes of binge-eating are characterised by:

- consuming an abnormally large amount of food in a short period of time and sense of lack of control over eating during the episode
- marked distress about the behavior
- feeling disgusted or guilty, or eating alone because of embarrassment.

Limitation of Use for BED:

Prescribers should consider that serious cardiovascular (CV) events have been reported with this class of sympathomimetic medications. The BED clinical trials were not designed to assess CV safety. While there is an accumulation of safety data with VYVANSE use in the Attention Deficit Hyperactivity Disorder (ADHD) population, this is of limited relevance regarding CV risk in the BED population. Given the higher CV risk associated with obesity, the BED population may be at a higher risk.

The safety and effectiveness of VYVANSE for the treatment of obesity have not been established. VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.

Dosing:

The recommended starting dose is 30 mg/day to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 to 70 mg/day. The maximum dose is 70 mg/day.

Consult the product monograph at www.shirecanada.com/vyvp/en for important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions, and dosing information. The product monograph is also available by calling Shire Pharma Canada ULC. at 1-800-268-2772.

Sincerely,

Glen Choma
Senior Product Manager, Neuroscience

References:

1. Shire Pharma Canada ULC. Data on file.
2. VYVANSE Product Monograph. Shire Pharma Canada ULC, September 30, 2016.
3. American Psychiatric Association. DSM-5[®] Fact Sheet. Feeding and eating disorders. <http://www.dsm5.org/documents/eating%20disorders%20fact%20sheet.pdf>. Accessed April 10, 2016.

* VYVANSE is a registered trade-mark used under licence from Shire LLC.
† DSM and DSM-5 are registered trademarks of the American Psychiatric Association.
© 2016 Shire Pharma Canada ULC. All rights reserved.
CDA/PRMCDA/VYV/16/0052
70463-12-2017-E

